Aurobindo Pharma inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMO), on June 3, 2026. The facility, located in Borapatla, Telangana, was unveiled in the presence of state ministers Shri D. Sridhar Babu and Shri Damodar Raja Narasimha. MSD has joined as the anchor customer for this new facility, which is designed to support both domestic and export markets subject to regulatory approvals.

The inauguration follows a meeting between the Directors of Aurobindo Pharma, senior leadership from MSD, and Telangana Chief Minister Shri Anumula Revanth Reddy. The state government's support was highlighted as a critical factor in establishing the facility, which aligns with its goal of positioning Telangana as a global centre for pharmaceuticals and biotechnology.

Facility Capabilities

TheraNym is equipped with advanced infrastructure designed to meet international regulatory standards. Key specifications of the facility are outlined below:

Dr. Satakarni Makkapati, CEO Biologics and Director of Aurobindo Pharma, stated that the facility is positioned to serve the supply chains of leading global pharmaceutical companies. He noted that the confidence shown by MSD serves as a mandate to deliver excellence in the expanding global biologics market.

Strategic Importance

The establishment of TheraNym marks Aurobindo Pharma's strategic entry into the biologics contract manufacturing segment. Mr. Nithyananda Reddy, Vice Chairman and MD, emphasized that this addition complements the company's existing biosimilars foray, CuraTeQ. He expressed gratitude to the Telangana government for its policy support and infrastructure facilitation through initiatives like the Telangana Life Sciences Policy and TSIIC.

Dr. Dave Maraldo, Executive Vice President and President of the MSD Manufacturing Division, highlighted that the partnership aims to strengthen global access to critical biologic medicines. The facility is expected to add meaningful capacity to the MSD supply chain, ensuring compliant and reliable product supply.

Aurobindo Pharma Limited will participate in the ICICI Securities India Investor Conference scheduled for June 8, 2026, in Mumbai, engaging with investors through in-person and group meetings. The interaction is part of the company's routine investor relations activities and provides a platform for management to discuss business performance and strategy. No unpublished price sensitive information (UPSI) is intended to be shared during these discussions, ensuring compliance with regulatory standards.

The meeting is scheduled to occur between 10:00 and 18:00 IST. Officials representing the pharmaceutical major will be present to address queries from attending investors. The company noted that the schedule remains subject to change due to exigencies on the part of the investors or the company itself.

Meeting Details

The following table outlines the key particulars of the scheduled investor interaction:

The disclosure was formally communicated to the exchanges by B. Adi Reddy, Company Secretary of Aurobindo Pharma Limited. The filing was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.